ECA
ALNY icon

Elevate Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Elevate Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,039
Closed -$413K – 74
2025
Q4 		$413K Buy
+1,039
New +$460K 0.27% 67

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Elevate Capital Advisors's ALNY Position: Q1 2026 in Review

Elevate Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,039 shares — an estimated $413K sold.

Elevate Capital Advisors first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $413K in Q4 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Elevate Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Elevate Capital Advisors sold 1,039 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $413K.
  • Elevate Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Elevate Capital Advisors's Alnylam Pharmaceuticals position peaked at $413K in Q4 2025.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Elevate Capital Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.